Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 1/20 | 0.41 |
| ▸ | DRD4 | P21917 | 3/20 | 0.41 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | UTS2R | Q9UKP6 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CCR5 | P51681 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4226684 | 0.80 | DRD4 (0.50) | CCR3DRD4S1PR5SMN1; SMN2KDM4E | |
| SCHEMBL1809411 | 0.80 | CCR3 (0.56) | CCR3DRD4S1PR5TP53CNR2 | |
| SCHEMBL1809409 | 0.80 | CCR3 (0.56) | CCR3DRD4S1PR5TP53CNR2 | |
| SCHEMBL4496189 | 0.78 | DRD4 (0.51) | CCR3DRD4S1PR5SMN1; SMN2KDM4E | |
| SCHEMBL1809405 | 0.77 | DRD4 (0.47) | CCR3DRD4S1PR5CNR2 | |
| SCHEMBL4220091 | 0.77 | DRD4 (0.45) | CCR3DRD4S1PR5TP53SMN1; SMN2 | |
| SCHEMBL4220802 | 0.75 | CCR3 (0.40) | CCR3DRD4S1PR5SMN1; SMN2KDM4E | |
| SCHEMBL4215944 | 0.74 | DRD4 (0.46) | CCR3DRD4S1PR5SMN1; SMN2UTS2R | |
| SCHEMBL1811279 | 0.73 | CCR3 (0.64) | CCR3DRD4SMN1; SMN2CXCR2ALDH1A1 | |
| SCHEMBL1811275 | 0.73 | CCR3 (0.64) | CCR3DRD4SMN1; SMN2CXCR2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090118288-A1 | N-Benzyl-Morpholine Derivatives as Modulators of the Chemokine Receptor | ASTRAZENECA AB (SE) | 2009-05-07 | — | — | US | disclosed |
| EP-1919884-A1 | N-BENZYL-MORPHOLINE DERIVATIVES AS MODULATORS OF THE CHEMOKINE RECEPTOR | AstraZeneca AB (SE) | 2008-05-14 | — | — | EP | disclosed |
| WO-2007011292-A1 | N-BENZYL-MORPHOLINE DERIVATIVES AS MODULATORS OF THE CHEMOKINE RECEPTOR | ASTRAZENECA AB (SE) | 2007-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118288-A1 | N-Benzyl-Morpholine Derivatives as Modulators of the Chemokine Receptor | CCR3, CCR1, CCR5 | CCR3 1/4885DRD4 1107/4885S1PR5 108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.